Aptose Biosciences Inc. (APTO)

Market Cap	5.23M
Revenue (ttm)	n/a
Net Income (ttm)	-35.80M
Shares Out	19.52M
EPS (ttm)	-2.55
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,027,030
Open	0.319
Previous Close	0.359
Day's Range	0.270 - 0.334
52-Week Range	0.270 - 2.910
Beta	1.36
Analysts	Strong Buy
Price Target	4.33 (+1,485.5%)
Earnings Date	Nov 8, 2024

About APTO

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. The company’s clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloid malignancies, such as acute myeloid leukemia and the higher risk myelodysplastic syndromes; and luxeptinib (CG-806), a potent oral small molecule,...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1986
• Employees: 36
• Stock Exchange: NASDAQ
• Ticker Symbol: APTO
• Website: https://www.aptose.com

Analyst Forecast

According to 3 analysts, the average rating for APTO stock is "Strong Buy." The 12-month stock price forecast is $4.33, which is an increase of 1,485.50% from the latest price.

Price Target

$4.33

(1,485.50% upside)

Analyst Consensus: Strong Buy